Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The aim of this study is to compare the levels of carcinoembryonic antigen (CEA) in the gastric juice, stomach mucosa and plasma of gastrectomy patients at risk of developing cancer with those in normal controls and gastric cancer subjects. Blood samples, gastric juices and biopsy material were taken from 52 patients (8 normal, 10 gastric carcinomas, 24 gastroresected according to Billroth II and 10 according to Billroth I). No significant correlation was found between age, sex or smoking habits and CEA levels in plasma, gastric juice or stomach mucosa. A significant correlation between CEA levels in gastric secretion and those in tissue emerged from out data (n = 52; r = 0.67; p less than 0.01). A minor correlation was found between tissue and plasma CEA values (r = 0.34; p less than 0.05). The mean levels of CEA in plasma did not show significant differences between controls and neoplastic risk subjects. The average level of CEA in gastric secretions and in tissue were significantly lower in normal controls than in neoplastic and gastroresected patients; in this latter group, we have observed a correlation between the severity of the histological lesions and the levels of CEA in the biopsy specimens; no correlation was found with the type of operation (Billroth I or Billroth II). The level of CEA in gastric juices and in biopsy material, therefore, appears to be more useful than in plasma in recognizing cancer risk subjects.
 ...
PMID:Evaluation of carcinoembryonic antigen levels in gastric juice, stomach mucosa and plasma in high-risk and gastric cancer patients. 370 60

Radioimmunologic assays of blood serum carcinoembryonic antigen (CEA) level were conducted at major stages of treatment of gastric cancer by subtotal stomach resection and gastrectomy with preliminary cryotreatment and thawing of tumor. A short-term rise in CEA level occurred in 53.9% of cases 3-4 days after combined therapy. A decrease in CEA concentration at discharge from hospital as compared with preoperative level and that registered 3-4 days after operation was observed in 50 and 75% of cases of combined therapy, respectively, and 47.5 and 37.5% of controls (surgery without cryotreatment). There was no correlation between cryotreatment and changes in CEA level in gastric ulcer patients.
 ...
PMID:[Dynamics of carcinoembryonic antigen in patients with stomach cancer during treatment with cryotherapy]. 371 72

A new mouse monoclonal antibody 9A3 (IgGl,K) raised against human poorly differentiated gastric adenocarcinoma cell line TMK-1 was produced. Immunohistochemically, 9A3 antibody reacted strongly with gastric carcinoma, colon carcinoma, pancreas carcinoma, lung carcinoma, breast carcinoma and cervical carcinoma of the uterus. This antibody did not react with various normal tissues from the whole body with the exception of neutrophils and macrophages. In fetal tissues, 9A3 antibody reacted with esophageal mucosa and colon epithelium, but did not react with purified carcinoembryonic antigen (CEA). The molecular weight of the antigen extracted with NP-40 from TMK-1 cells was estimated to be about 46,000 daltons by SDS-PAGE. The 9A3 antigen was also detected in conditioned tissue culture medium of the TMK-1 cell line and sera of gastric cancer patients and tumor imaging could be performed in xenotransplantable human gastric carcinoma in nude mice. In summary, 9A3 antibody may serve as a new marker for detection of cancer by immunohistochemical, cytological techniques and serologically in the sera of cancer patients.
 ...
PMID:[Monoclonal antibody 9A3 raised against a human poorly differentiated gastric adenocarcinoma cell line]. 372 60

Levels of carcinoembryonic antigen (CEA) and immunoglobin (Ig) in gastric juice of 93 patients with benign and malignant gastric diseases were assayed. The CEA level in gastric cancer patients (55.73 +/- 38.26 ng/ml) was obviously higher than that in peptic ulcer (15.51 +/- 12.09 ng/ml) and superficial gastritis (26.96 +/- 20.17 ng/ml). But no significant difference was found between the CEA levels of gastric cancer and chronic atrophic gastritis (48.66 +/- 31.87 ng/ml). Also, elevated CEA was closely correlated to intestinal metaplasia. The positive rate of Ig was significantly higher in gastric cancer (IgG greater than or equal to 185 ug/ml, IgA greater than or equal to 100 ug/ml) than in benign gastric diseases. Although no correlation is present in the CEA and Ig in gastric juice, the combination of these two methods could improve the diagnostic accuracy. We believe that the two assays are worthy for screening gastric cancer from patients with high risk, and for identifying precancerous lesions.
 ...
PMID:[Carcinoembryonic antigen and immunoglobin in gastric juice in the diagnosis of gastric cancer]. 375 41

The clinical validity of monitoring the tumor markers carcinoembryonic antigen (CEA) and CA 19-9 were investigated in 602 patients with colorectal, gastric, and pancreatic carcinomas. Sensitivity and specificity of the tests were evaluated preoperatively as well as in the postoperative follow-up for early detection of disease progression and recurrence. At a 95% level of specificity as calculated from a group of 150 patients with benign diseases, the CEA test with monoclonal antibody had a preoperative sensitivity of 39% in colorectal cancer and 21% in gastric cancer. On the other hand, CA 19-9 had a sensitivity of 19% in colorectal cancer, 21% in gastric cancer, and 89% in pancreatic cancer. In the postoperative follow-up it was found that a combination of both tumor marker tests was most profitable in gastric carcinomas, yielding an increase of sensitivity from 59%-94%, showing a high degree of complementarity. The gain in sensitivity provided by the CA 19-9 test over the CEA-test in colorectal cancer was very low. The gain in sensitivity, however, provided by the CEA test over the CA 19-9 test in pancreatic carcinoma was also very low. On the basis of these results it has to be recommended that cases with pancreatic carcinoma are to be monitored most efficiently with the CA 19-9 test, whereas in cases with colorectal cancer the CEA test should be used primarily. However, in gastric cancer the combined use of CEA and CA 19-9 represents a highly valuable basis for monitoring the course of disease.
 ...
PMID:The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. 385 76

A 35-year-old woman tuffering from gastric cancer associated with disseminated carcinomatosis of the bone marrow is reported. Total gastrectomy combined with splenectomy and distal pancreatectomy was performed. The patient was treated with mitomycin C, FT-207, OK-432, and PSK. But serum ALP (alkaline phosphatase) and CEA (carcinoembryonic antigen) values showed gradual elevations followed by deterioration of the patient's general condition. Consequently, chemotherapy program consisting of 5-fluorouracil, Adriamycin (intra-arterially), and cisplatin (intravenously) was initiated. Serum CEA and ALP values were considerably improved, and patient was restored to a better condition. She survived 17 months and died of disseminated intravascular coagulation.
 ...
PMID:[Effective postoperative chemotherapy of gastric cancer associated with disseminated carcinomatosis of the bone marrow]. 393 24

The authors recently established a new simple enzymatic assay method for total urinary polyamines (Cancer Res 1983; 43:2263-2367). In order to assess the clinical usefulness of measuring total urinary polyamines for the detection of cancer, this method has been applied to the assay of polyamines in the urine of 45 patients with stomach cancer who were classified as to clinical stage. In addition, the value of serum carcinoembryonic antigen (CEA) in the same individual patients was measured for comparison. Percentage of patients with elevated levels of total urinary polyamines increased with International Union Against Cancer (UICC) clinical stage, and was 40.0% (6/15), 50% (3/6), 72.7% (8/11), and 84.6% (11/13) for Stage I, II, III and IV stomach cancer patients, respectively. In 32 patients with stomach cancer of potentially operable Stage I, II, and III, elevated levels of total urinary polyamines were found in 17 patients and elevated levels of serum CEA were found in 5 patients. In 13 patients with inoperable stage IV stomach cancer, elevated levels of total urinary polyamines were found in 11 patients and elevated levels of serum CEA were found in 5 patients. Statistical differences in the detection rate were found between the two markers in these two groups of patients. The combination of these two markers did not increase the detection rate of stomach cancer significantly. The data indicate that the determination of total urinary polyamines by the new assay is clinically useful as a potential marker for the detection of advanced stages of stomach cancer and may be more useful than that of serum CEA. Furthermore, this study demonstrates the relationship between urinary polyamine levels and tumor regression and also the prognostic significance of polyamine determination in stomach cancer patients. In 6 of 13 patients who showed elevated levels of urinary polyamines before surgery, polyamine levels fell to within the normal range after successful surgical removal of tumor. In general, each polyamine level decreased significantly following surgery by paired Student's t test analysis. All of the five Stage IV patients with polyamine levels greater than 4.0 mumol/kg/24 hour died in less than 3 months whereas five of eight Stage IV patients with polyamine levels less than or equal to 4.0 mumol/kg/24 hour survived 10 to 20 months. Statistical differences in survival were observed between Stage IV patients with polyamine levels greater than 4.0 mumol/kg/24 hour and those with polyamine levels less than or equal to 4.0 mumol/kg/24 hour.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:The value of urinary polyamine assay in stomach cancer. Comparison with serum carcinoembryonic antigen. 402 98

Two monoclonal antibodies antitumor-associated antigens, B1.1 and B72.3, have been used with the immunoperoxidase technique on tissue sections to study gastric carcinomas, dysplasia, intestinal metaplasia, and adenomas. B1.1 reacts with carcinoembryonic antigen (CEA); B72.3 reacts with a 220-400 kd glycoprotein present in colon, breast, and other carcinomas. CEA was found in 89% (34 of 38) and B72.3 antigen in 92% (35 of 38) of carcinomas. In half of these more than 50% of tumor cells were positive. The normal epithelium was usually negative or sporadically positive in a few cells. In dysplastic areas and adenomas the number of cells that were positive for the two antigens was greater than in normal epithelium and smaller than in carcinomas. In intestinal metaplasia B72.3 antigen was almost always present, whereas CEA was sometimes undetectable. Both the antigens proved to be good markers of neoplastic versus normal cells. The presence of B72.3 antigen in addition to CEA in dysplasia, adenomas, and intestinal metaplasia adds further evidence of their close relationship with gastric cancer.
 ...
PMID:Distribution of two tumor-associated antigens in gastric lesions as detected by two monoclonal antibodies on tissue sections. 406 40

Pregnancy-associated alpha 2-glycoprotein (alpha 2-PAG) levels were measured in human sera by a modification of Laurell's electroimmunoassay using rabbit anti-alpha 2-PAG serum. Sera were obtained from healthy controls (32 males and 46 females), patients with benign breast diseases (55 cases), and patients with breast (82 cases), gastric (89 cases), or colorectal (22 cases) cancers. In healthy controls, the mean alpha 2-PAG value for females was higher than that for males (p less than 0.05), so alpha 2-PAG values for males and females were considered separately in this study. Serum alpha 2-PAG levels in patients with benign breast tumors were almost the same as those of controls. In patients with primary breast and gastric cancer, alpha 2-PAG levels were higher than those of controls (p less than 0.005) and tended to increase with progress of the disease. Raised alpha 2-PAG levels decreased in these patients after curative surgery. These results show that serum alpha 2-PAG is useful as a marker in both the initial diagnosis and follow-up of breast and gastric cancer. The reliability of alpha 2-PAG as a tumor-associated marker was reinforced by comparison of the positive rates of the three parameters alpha 2-PAG, carcinoembryonic antigen (CEA), and immunosuppressive acidic protein (IAP) in patients with breast and gastric cancer.
 ...
PMID:Significance of pregnancy-associated alpha 2-glycoprotein (alpha 2-PAG) in patients with breast, gastric and colorectal cancer. 617 10

A radiometric immunoassay for detecting colon-specific antigen-p (CSAp) in the blood of patients suspected of having colorectal cancer has been developed and evaluated in 272 subjects of various disease entities. Using 10 units/ml as the cutoff value for normalcy, the results indicate that the highest number of elevated CSAp titers occurred in patients with advanced colorectal cancer (61%). Only one of 12 colonic adenoma patients had an elevated CSAp titer, and this was slightly above the 10 units/ml cutoff. Other nonneoplastic gastrointestinal disorders showed an 18% abnormal CSAp titer frequency, of which more than half bordered the upper limit of normalcy. CSAp elevations were also found in gastric cancer (20%), pancreatic cancer (20%), breast cancer (5%), and normal individuals (3%). CSAp was compared to carcinoembryonic antigen (CEA) in 44 colorectal cancer patients, in 12 patients with colonic adenomas, and in 62 patients with diverse gastrointestinal disorders. Using a CEA cutoff of 5 ng/ml, CSAp could increase the diagnostic accuracy of the CEA plasma test in colorectal cancer patients by 14%. In patients with colonic adenomas, the CSAp titer was normal when the CEA value was elevated in 25% of the cases. However, both were simultaneously elevated in only 3% of the patients with benign gastrointestinal disorders. Since the CSAp test was less frequently elevated (0-7%) in patients with breast, ovarian, lung, or cervical cancer than was found for CEA (39-75% elevated), it seems that the CSAp blood assay detects colorectal cancer more specifically than the more generally distributed CEA. These results suggest that the combined use of blood CEA and CSAp could enhance the discrimination of colorectal cancers from other nonmalignant gastrointestinal diseases, and could also serve to enhance the colorectal cancer-specificity of the CEA assay. Furthermore, serial monitoring of both markers in four advanced colorectal cancer patients indicated that they reflect disease activity, falling after successful treatment and rising again with recurrence and disease progression.
 ...
PMID:Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer. 617 98


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>